- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04680715
Per-Operative Radiotherapy by Papillon +TM in Localized Breast Cancer (RPOS+2)
November 8, 2023 updated by: Centre Antoine Lacassagne
Per-Operative Radiotherapy (RPO) by Papillon +TM in Localized Breast Cancer : Faisability and Toxicity Study
Phase II study; open recruitment, multicentrique.
The aim of this clinical research is to evaluate faisability and toxicity of the per-operative radiotherapy using PAPILLON + TM device for localized breast cancers patients over 65 years.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Frédérique JACQUINOT
- Phone Number: +33 04 92 03 10 24
- Email: drci-promotion@nice.unicancer.fr
Study Locations
-
-
-
Clermont-Ferrand, France, 63000
- Not yet recruiting
- Pôle Santé République
-
Contact:
- Annie ITIE
-
Principal Investigator:
- Vivien FUNG, Dr
-
Nice, France, 06189
- Recruiting
- Centre Antoine Lacassagne
-
Contact:
- Damien CHAUVIERE
- Phone Number: +33 0492031365
-
Principal Investigator:
- Marie-Eve FOUCHE-CHAND, Dr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
65 years and older (Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patient with invasive ductal adenocarcinoma <=2cm, evaluate on all radiological exams;
- Women aged 65 years or older (patients 65 years of age in the year may be included);
- Grade 1 or 2 unifocal adenocarcinoma, all index KI67, positive HR, negative HER2 status;
- T0 or T1, N0 radio-clinic;
- Operable patient with breast volume compatible with conservative surgery;
- Patient with prior malignancy or other concurrent malignancies are eligible, including bilateral breast cancer
- Patients who have been made aware of the information sheet and have given their written signed informed consent;
- Patients benefitting from social health insurance coverage
Exclusion Criteria:
- Age less than 65 years (except if 65 years obtained during the year)
- Patient with an exclusive in situ carcinoma
- Patient with lymphatic invasion / peri-nerve involvement / vascular emboli
- Patient with a lobular adenocarcinoma
- Patient with metastatic disease
- Multifocal tumor
- Patient with grade 3 or N+ disease
- N1 proved by ultrasound guided
- patient unable to express her consent
- Patient deprived placed under the authority of a tutor
- Female patients who are pregnant or breastfeeding
- Vulnerable patient: as defined in article L1121-5 à -8
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Per-Operative Radiotherapy technique by Papillon +TM
Per-Operative Radiotherapy (1x20Gy) technique by Papillon +TM
|
20Gy Per-Operative Radiotherapy technique by Papillon +TM, on localized breast cancer
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
early toxicities occuring until 6 months after performing per-operative radiotherapy
Time Frame: up to 6 months
|
pourcentage of patient with toxicities of grade 3 and more (by CTCAE v5.0) related to per-operative radiotherapy and that occured until 6 months after performing
|
up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
global tolerance of per-operative radiotherapy
Time Frame: up to 5 years
|
global safety (assessed by CTCAE V5.0) of per-operative radiotherapy
|
up to 5 years
|
local disease free survival at 5 years of per-operative radiotherapy
Time Frame: up to 5 years
|
To evaluate local disease free survival at 5 years of per-operative radiotherapy
|
up to 5 years
|
disease free survival at 5 years of per-operative radiotherapy
Time Frame: up to 5 years
|
To evaluate disease free survival at 5 years of per-operative radiotherapy
|
up to 5 years
|
quality of life of patients
Time Frame: up to 6 months
|
QLQ-C30 and QLQ BR-23 EORTC questionnaires
|
up to 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 16, 2021
Primary Completion (Estimated)
June 1, 2027
Study Completion (Estimated)
June 1, 2028
Study Registration Dates
First Submitted
November 18, 2020
First Submitted That Met QC Criteria
December 17, 2020
First Posted (Actual)
December 23, 2020
Study Record Updates
Last Update Posted (Estimated)
November 9, 2023
Last Update Submitted That Met QC Criteria
November 8, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020/33
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Localized Breast Cancer
-
Centre Georges Francois LeclercRecruiting
-
Centre Antoine LacassagneActive, not recruitingLocalized Breast CancerFrance
-
University of Southern CaliforniaNational Cancer Institute (NCI)Not yet recruitingAnatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage 0 Breast Cancer AJCC v8 | Localized Breast CarcinomaUnited States
-
Arizona Oncology ServicesUnknownLocalized Breast Cancer | Localized Prostate Cancer | Patients Receiving External Beam RadiotherapyUnited States
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH); NRG OncologyActive, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Breast Carcinoma | Triple-Negative Breast Carcinoma | HER2-Negative Breast Carcinoma | Bilateral Breast Carcinoma | Localized Breast CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedAdvanced Adult Primary Liver Cancer | Localized Extrahepatic Bile Duct Cancer | Localized Gallbladder Cancer | Localized Resectable Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Recurrent... and other conditionsUnited States
-
Northwestern UniversityTerminated
-
Jonsson Comprehensive Cancer CenterBayerCompletedLocalized Resectable Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular CarcinomaUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
Clinical Trials on Per-Operative Radiotherapy technique by Papillon +TM
-
Centre Leon BerardRoche Pharma AGRecruitingSarcoma,Soft TissueFrance, United Kingdom
-
Boston Children's HospitalChildren's Hospital of Philadelphia; Washington University School of Medicine; The Cleveland Clinic and other collaboratorsActive, not recruitingAnterior Cruciate Ligament ReconstructionUnited States